- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
GlaxoSmithKline Pharmaceuticals Limited has announced a board meeting to discuss and approve the financial results for the quarter and nine months ended 31 December 2024. Notable figures include a standalone revenue of ₹946.36 crore, a net profit after tax of ₹228.58 crore, and earnings per share (EPS) of ₹13.49 for the quarter. The company continues to demonstrate resilience in its performance metrics, which could generate a positive outlook among investors. With strong revenue growth and profitability, GSK is well-positioned for future expansion and may attract increased interest from shareholders.
All announcements from GlaxoSmithKline Pharmaceuticals Limited